Merck & Co. reported Tuesday that fourth-quarter profit plunged 58% despite higher revenues as the drugmaker took a slew of charges for restructuring costs, an acquisition and increased legal reserves, mainly for its withdrawn painkiller Vioxx.
*For more on this story,
read the full Associated Press article.
